Artemisinin and its derivatives can significantly inhibit lung tumorigenesis and tumor metastasis through Wnt/β-catenin signaling

This publication has 55 references indexed in Scilit:

• Frizzled-8 receptor is activated by the Wnt-2 ligand in non-small cell lung cancer
  BMC Cancer, 2013
• Lineage tracing with Axin2 reveals distinct developmental and adult populations of Wnt/β-catenin–responsive neural stem cells
  Proceedings of the National Academy of Sciences, 2013
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
  The Lancet Oncology, 2012
• Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration
  Malaria Journal, 2011
• Myristoylated Naked2 Antagonizes Wnt-β-Catenin Activity by Degrading Dishevelled-1 at the Plasma Membrane
  Journal of Biological Chemistry, 2010
• Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria
  Nature Reviews Microbiology, 2009
• Pre-referral rectal artesunate to prevent death and disability in severe malaria: a placebo-controlled trial
  The Lancet, 2009
• Rectal Administration of Artemisinin Derivatives for the Treatment of Malaria
  JAMA, 2007
• Nanog and transcriptional networks in embryonic stem cell pluripotency
  Cell Research, 2007
• Cancer chemoprevention with dietary phytochemicals
  Nature Reviews Cancer, 2003